Drug intelligence / Profile preview

microRNA-129-3p mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

MicroRNA-129-3p mimic is a synthetic, double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous mature microRNA miR-129-3p. As a research-grade biologic, it is utilized in functional studies to investigate the tumor-suppressive roles of miR-129-3p, which is frequently downregulated in various malignancies. The mimic functions by binding to the 3' untranslated regions (UTRs) of specific target mRNAs, leading to translational repression or mRNA degradation. Key targets identified in preclinical models include E2F5 in glioblastoma, BZW1 in ovarian cancer, and Wip1 (PPM1D) in intrahepatic cholangiocarcinoma. In head and neck squamous cell carcinoma (HNSCC), miR-129-3p mimic has been shown to suppress cell proliferation, invasion, and migration while enhancing sensitivity to cisplatin and radiotherapy. It is currently available as a laboratory tool from suppliers such as Thermo Fisher Scientific and MedChemExpress and is not yet an approved therapeutic product.

Other names
miR-129-3p mimicmiR129-3p mimicmiR 129-3p mimichsa-miR-129-3p mimichsa-miR129-3p mimichsa-miR 129-3p mimicmicroRNA-129-3pmicroRNA129-3pmicroRNA 129-3p
02

Targets

PPM1D (Protein phosphatase, Mg2+/Mn2+ dependent 1D)E2F transcription factor 5 mRNA 3'-untranslated regionBZW1 (Basic leucine zipper and W2 domain-containing protein 1)

Beyond the preview

Go deeper on microRNA-129-3p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA-129-3p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call